
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="DB2B421B9265B1133C421B0010997DE3.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="esmo">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10774963/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="ESMO Open">
<meta name="citation_title" content="Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study">
<meta name="citation_author" content="S Joris">
<meta name="citation_author_institution" content="Department of Medical Oncology, UZ Brussel, Brussels">
<meta name="citation_author" content="H Denys">
<meta name="citation_author_institution" content="Department of Medical Oncology, University Hospital Ghent, Ghent">
<meta name="citation_author" content="J Collignon">
<meta name="citation_author_institution" content="CHU Sart Tilman, Liège">
<meta name="citation_author" content="M Rasschaert">
<meta name="citation_author_institution" content="UZA, Antwerpen">
<meta name="citation_author" content="D T’Kint de Roodenbeke">
<meta name="citation_author_institution" content="Institut Jules Bordet-Université libre de Bruxelles, Brussels">
<meta name="citation_author" content="FP Duhoux">
<meta name="citation_author_institution" content="Cliniques universitaires Saint-Luc, Brussels">
<meta name="citation_author" content="J-L Canon">
<meta name="citation_author_institution" content="GHdC, Charlerloi">
<meta name="citation_author" content="S Tejpar">
<meta name="citation_author_institution" content="UZ Leuven, Leuven">
<meta name="citation_author" content="J Mebis">
<meta name="citation_author_institution" content="Jessa Ziekenhuizen, Hasselt">
<meta name="citation_author" content="L Decoster">
<meta name="citation_author_institution" content="Department of Medical Oncology, UZ Brussel, Brussels">
<meta name="citation_author" content="P Aftimos">
<meta name="citation_author_institution" content="Institut Jules Bordet-Université libre de Bruxelles, Brussels">
<meta name="citation_author" content="J De Grève">
<meta name="citation_author_institution" content="Department of Medical Oncology, UZ Brussel, Brussels">
<meta name="citation_author_institution" content="Department of Medical Genetics, UZ Brussel, Brussels, Belgium">
<meta name="citation_publication_date" content="2023 Oct 16">
<meta name="citation_volume" content="8">
<meta name="citation_issue" content="6">
<meta name="citation_firstpage" content="102041">
<meta name="citation_doi" content="10.1016/j.esmoop.2023.102041">
<meta name="citation_pmid" content="37852034">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC10774963/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC10774963/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC10774963/pdf/main.pdf">
<meta name="description" content="The Belgian Precision initiative aims to maximize the implementation of tumor-agnostic next-generation sequencing in patients with advanced cancer and enhance access to molecularly guided treatment options. Academic tumor-agnostic basket phase II ...">
<meta name="og:title" content="Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="The Belgian Precision initiative aims to maximize the implementation of tumor-agnostic next-generation sequencing in patients with advanced cancer and enhance access to molecularly guided treatment options. Academic tumor-agnostic basket phase II ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC10774963/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://pmc.ncbi.nlm.nih.gov/search/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="10774963">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1016/j.esmoop.2023.102041"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/main.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC10774963%2F%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/10774963/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/10774963/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC10774963/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-esmo.gif" alt="ESMO Open logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to ESMO Open" title="Link to ESMO Open" shape="default" href="http://esmoopen.bmj.com/" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">ESMO Open</button></div>. 2023 Oct 16;8(6):102041. doi: <a href="https://doi.org/10.1016/j.esmoop.2023.102041" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1016/j.esmoop.2023.102041</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://pmc.ncbi.nlm.nih.gov/search/?term=%22ESMO%20Open%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22ESMO%20Open%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22ESMO%20Open%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22ESMO%20Open%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Efficacy of olaparib in advanced cancers with germline or somatic mutations in <em>BRCA1</em>, <em>BRCA2</em>, <em>CHEK2</em> and <em>ATM</em>, a Belgian Precision tumor-agnostic phase II study</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Joris%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">S Joris</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">S Joris</span></h3>
<div class="p">
<sup>1</sup>Department of Medical Oncology, UZ Brussel, Brussels</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Joris%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">S Joris</span></a>
</div>
</div>
<sup>1,</sup><sup>∗</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Denys%20H%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">H Denys</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">H Denys</span></h3>
<div class="p">
<sup>2</sup>Department of Medical Oncology, University Hospital Ghent, Ghent</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Denys%20H%22%5BAuthor%5D" class="usa-link"><span class="name western">H Denys</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Collignon%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">J Collignon</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">J Collignon</span></h3>
<div class="p">
<sup>3</sup>CHU Sart Tilman, Liège</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Collignon%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">J Collignon</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Rasschaert%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">M Rasschaert</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">M Rasschaert</span></h3>
<div class="p">
<sup>4</sup>UZA, Antwerpen</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Rasschaert%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">M Rasschaert</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22T%E2%80%99Kint%20de%20Roodenbeke%20D%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">D T’Kint de Roodenbeke</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">D T’Kint de Roodenbeke</span></h3>
<div class="p">
<sup>5</sup>Institut Jules Bordet-Université libre de Bruxelles, Brussels</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22T%E2%80%99Kint%20de%20Roodenbeke%20D%22%5BAuthor%5D" class="usa-link"><span class="name western">D T’Kint de Roodenbeke</span></a>
</div>
</div>
<sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Duhoux%20FP%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">FP Duhoux</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">FP Duhoux</span></h3>
<div class="p">
<sup>6</sup>Cliniques universitaires Saint-Luc, Brussels</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Duhoux%20FP%22%5BAuthor%5D" class="usa-link"><span class="name western">FP Duhoux</span></a>
</div>
</div>
<sup>6</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Canon%20JL%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">J-L Canon</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">J-L Canon</span></h3>
<div class="p">
<sup>7</sup>GHdC, Charlerloi</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Canon%20JL%22%5BAuthor%5D" class="usa-link"><span class="name western">J-L Canon</span></a>
</div>
</div>
<sup>7</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Tejpar%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">S Tejpar</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">S Tejpar</span></h3>
<div class="p">
<sup>8</sup>UZ Leuven, Leuven</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Tejpar%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">S Tejpar</span></a>
</div>
</div>
<sup>8</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mebis%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">J Mebis</span></a><div hidden="hidden" id="id9">
<h3><span class="name western">J Mebis</span></h3>
<div class="p">
<sup>9</sup>Jessa Ziekenhuizen, Hasselt</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mebis%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">J Mebis</span></a>
</div>
</div>
<sup>9</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Decoster%20L%22%5BAuthor%5D" class="usa-link" aria-describedby="id10"><span class="name western">L Decoster</span></a><div hidden="hidden" id="id10">
<h3><span class="name western">L Decoster</span></h3>
<div class="p">
<sup>1</sup>Department of Medical Oncology, UZ Brussel, Brussels</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Decoster%20L%22%5BAuthor%5D" class="usa-link"><span class="name western">L Decoster</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Aftimos%20P%22%5BAuthor%5D" class="usa-link" aria-describedby="id11"><span class="name western">P Aftimos</span></a><div hidden="hidden" id="id11">
<h3><span class="name western">P Aftimos</span></h3>
<div class="p">
<sup>5</sup>Institut Jules Bordet-Université libre de Bruxelles, Brussels</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Aftimos%20P%22%5BAuthor%5D" class="usa-link"><span class="name western">P Aftimos</span></a>
</div>
</div>
<sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22De%20Gr%C3%A8ve%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id12"><span class="name western">J De Grève</span></a><div hidden="hidden" id="id12">
<h3><span class="name western">J De Grève</span></h3>
<div class="p">
<sup>1</sup>Department of Medical Oncology, UZ Brussel, Brussels</div>
<div class="p">
<sup>10</sup>Department of Medical Genetics, UZ Brussel, Brussels, Belgium</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22De%20Gr%C3%A8ve%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">J De Grève</span></a>
</div>
</div>
<sup>1,</sup><sup>10</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="aff1">
<sup>1</sup>Department of Medical Oncology, UZ Brussel, Brussels</div>
<div id="aff2">
<sup>2</sup>Department of Medical Oncology, University Hospital Ghent, Ghent</div>
<div id="aff3">
<sup>3</sup>CHU Sart Tilman, Liège</div>
<div id="aff4">
<sup>4</sup>UZA, Antwerpen</div>
<div id="aff5">
<sup>5</sup>Institut Jules Bordet-Université libre de Bruxelles, Brussels</div>
<div id="aff6">
<sup>6</sup>Cliniques universitaires Saint-Luc, Brussels</div>
<div id="aff7">
<sup>7</sup>GHdC, Charlerloi</div>
<div id="aff8">
<sup>8</sup>UZ Leuven, Leuven</div>
<div id="aff9">
<sup>9</sup>Jessa Ziekenhuizen, Hasselt</div>
<div id="aff10">
<sup>10</sup>Department of Medical Genetics, UZ Brussel, Brussels, Belgium</div>
<div class="author-notes p"><div class="fn" id="cor1">
<sup>∗</sup><p class="display-inline"><em>Correspondence to:</em> Dr Sofie Joris, Department of Medical Oncology, UZ Brussel, Laarbeeklaan 101, 1090 Jette, Brussels, Belgium <span>Sofie.Joris@uzbrussel.be</span></p>
</div></div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Collection date 2023 Dec.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© 2023 The Author(s)</div>
<p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC10774963  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37852034/" class="usa-link">37852034</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abs0010"><h2>Abstract</h2>
<section id="sec1_pmc"><h3 class="pmc_sec_title">Background</h3>
<p>The Belgian Precision initiative aims to maximize the implementation of tumor-agnostic next-generation sequencing in patients with advanced cancer and enhance access to molecularly guided treatment options. Academic tumor-agnostic basket phase II studies are part of this initiative. The current investigator-driven trial aimed to investigate the efficacy of olaparib in advanced cancers with a (likely) pathogenic mutation (germline or somatic) in a gene that plays a role in homologous recombination (HR).</p></section><section id="sec2_pmc"><h3 class="pmc_sec_title">Patients and methods</h3>
<p>This open-label, multi-cohort, phase II study examines the efficacy of olaparib in patients with an HR gene mutation in their tumor and disease progression on standard of care. Patients with a somatic or germline mutation in the same gene define a cohort. For each cohort, a Simon minimax two-stage design was used. If a response was observed in the first 13 patients, 14 additional patients were included. Here, we report the results on four completed cohorts: patients with a <em>BRCA1</em>, <em>BRCA2</em>, <em>CHEK2</em> or <em>ATM</em> mutation.</p></section><section id="sec3_pmc"><h3 class="pmc_sec_title">Results</h3>
<p>The overall objective response rate across different tumor types was 11% in the <em>BRCA1-</em>mutated (<em>n</em> = 27) and 21% in the <em>BRCA2</em>-mutated (<em>n</em> = 27) cohorts. Partial responses were seen in pancreatic cancer, gallbladder cancer, endocrine carcinoma of the pancreas and parathyroid cancer. One patient with a <em>BRCA2</em> germline-mutated colon cancer has an ongoing complete response with 19+ months on treatment. Median progression-free survival in responding patients was 14+ months (5-34+ months). The clinical benefit rate was 63% in the <em>BRCA1-</em>mutated and 46% in the <em>BRCA2</em>-mutated cohorts. No clinical activity was observed in the <em>ATM</em> (<em>n</em> = 13) and <em>CHEK2</em> (<em>n</em> = 14) cohorts.</p></section><section id="sec4_pmc"><h3 class="pmc_sec_title">Conclusion</h3>
<p>Olaparib showed efficacy in different cancer types harboring somatic or germline mutations in the <em>BRCA1/2</em> genes but not in <em>ATM</em> and <em>CHEK2</em>. Patients with any cancer type harboring <em>BRCA1/2</em> mutations should have access to olaparib.</p></section><section id="kwrds0010" class="kwd-group"><p><strong>Key words:</strong> agnostic NGS, olaparib, colorectal cancer, parathyroid cancer, biliary tract cancer, BRCA1, BRCA2, CHEK2, ATM</p></section></section><section class="abstract" id="abs0015"><h2>Highlights</h2>
<ul id="ulist0010" class="list" style="list-style-type:none">
<li id="u0010">
<span class="label">•</span><p class="display-inline" id="p0010">Advanced cancer patients harboring somatic or germline <em>BRCA1/2</em> mutations respond to treatment with olaparib.</p>
</li>
<li id="u0015">
<span class="label">•</span><p class="display-inline" id="p0015">Response to olaparib in the presence of a <em>BRCA1/2</em> mutation is seen in any cancer type.</p>
</li>
<li id="u0020">
<span class="label">•</span><p class="display-inline" id="p0020">Olaparib does not have clinically meaningful activity in cancers with an <em>ATM</em> or <em>CHEK2</em> mutation.</p>
</li>
</ul></section><section id="sec1"><h2 class="pmc_sec_title">Introduction</h2>
<p id="p0025">The mutational landscape of cancer is rapidly evolving, and next-generation sequencing (NGS) of solid tumors in various projects increasingly reveals mutations in cancer genes. It is currently estimated that &gt;50% of cancers could harbor actionable mutations.<a href="#bib1" class="usa-link" aria-describedby="bib1"><sup>1</sup></a> The Belgian Society of Medical Oncology (BSMO), in collaboration with the different university oncological centers, major regional hospitals and other stakeholders, has launched a national Precision initiative to, firstly, promote the implementation of NGS in Belgian cancer patients and, secondly, establish a fluent path for patients’ access to drugs that match the genotype of their cancer.<a href="#bib2" class="usa-link" aria-describedby="bib2"><sup>2</sup></a> A part of the initiative was to organize tumor-agnostic basket phase II studies in specific cancer gene mutations. One of these studies recruited patients with a homologous recombination (HR) deficiency (HRD) gene mutation for treatment with olaparib. Completed cohorts of patients with a <em>BRCA1/2</em>, <em>ATM</em> or <em>CHEK2</em> mutation are reported here.</p>
<p id="p0030">During each cell division, the DNA replication machinery has a risk of error in response to which cells have developed complex systems to detect and repair these errors. When these mechanisms fail, the DNA damage response is disrupted, allowing damaged cells to survive and in some cases progress to uncontrolled cell proliferation. Dysregulation of DNA damage repair (DDR) also causes genomic instability, a hallmark of cancer.<a href="#bib3" class="usa-link" aria-describedby="bib3"><sup>3</sup></a><sup>,</sup><a href="#bib4" class="usa-link" aria-describedby="bib4"><sup>4</sup></a> On the contrary, failure of DDR is a weakness that can be targeted therapeutically, as in the case of the poly (ADP-ribose) polymerase inhibitor (PARPi), olaparib.</p>
<p id="p0035">Olaparib was the first PARPi to be discovered and subsequently developed. The SOLO-1 trial,<a href="#bib5" class="usa-link" aria-describedby="bib5"><sup>5</sup></a> recently updated with overall survival results, brought on the first registered indication for olaparib in ovarian cancer patients who harbor a <em>BRCA1/2</em> mutation in their tumor. Later, it was also approved for the treatment of advanced and early breast cancer,<a href="#bib6" class="usa-link" aria-describedby="bib6"><sup>6</sup></a><sup>,</sup><a href="#bib7" class="usa-link" aria-describedby="bib7"><sup>7</sup></a> advanced prostate cancer<a href="#bib8" class="usa-link" aria-describedby="bib8"><sup>8</sup></a> and pancreatic cancer<a href="#bib9" class="usa-link" aria-describedby="bib9"><sup>9</sup></a> in the presence of a <em>BRCA1</em> or <em>BRCA2</em> mutation. The Food and Drug Administration approval for olaparib with regard to prostate cancer also includes additional homologous recombination repair (HRR) genes.</p>
<p id="p0040">PARPi responses have also been documented in cancers where no <em>BRCA1/2</em> mutations were found, indicating molecular features shared with BRCA-mutant tumors. Other HRDs likely cause such sensitivities.<a href="#bib10" class="usa-link" aria-describedby="bib10"><sup>10</sup></a><sup>,</sup><a href="#bib11" class="usa-link" aria-describedby="bib11"><sup>11</sup></a> When inactivated by mutation, genes that cause HRD include <em>ATM</em>, <em>CHEK1</em>, <em>CHEK2</em>, <em>NBN</em>, <em>BRIP1</em>, <em>MRE11A</em>, <em>RAD50</em>, <em>RAD51B</em>, <em>RAD51C</em>, <em>RAD51D</em>, <em>RAD54L</em>, <em>PALB2</em>, <em>BARD1</em>, <em>FAM175A</em>, <em>CDK12</em>, <em>FANC</em>L, <em>TP53</em> (only germline) and <em>PPP2R2A</em>. This list is not limitative as other genes can, directly or indirectly, cause HRD. HR gene mutations can be found in all cancer types.<a href="#bib12" class="usa-link" aria-describedby="bib12"><sup>12</sup></a></p></section><section id="sec2"><h2 class="pmc_sec_title">Patients and methods</h2>
<section id="sec2.1"><h3 class="pmc_sec_title">Study design and patient population</h3>
<p id="p0045">The cohorts reported here are part of an academic multicenter basket phase II study designed to investigate olaparib’s efficacy in any type of HR-deficient cancer. The study was approved by the ethical committee (EC) of every participating site (EC number 2018/442). Before entering the study, patients signed an informed consent form. Recruitment started on 1 February 2019 and ended on 1 February 2023.</p>
<p id="p0050">The BSMO organized the study that recruited patients from Belgian oncological centers. The participating trial sites, 12 in total, were all university and large regional hospitals with clinical trial experience (see <a href="#appsec1" class="usa-link">Appendix 1</a> for the list of the sites and their primary investigator).</p>
<p id="p0055">Eligible patients were initially identified as a proband or a relative in families where a germline mutation was found in the context of diagnostic or predictive genetic testing or when a mutation was detected on historical tumor sequencing. That pathway led initially to a slow accrual. The accrual was drastically accelerated after the Geneo study was initiated. The Geneo study (<a href="https://clinicaltrials.gov/ct2/show/NCT04641676" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT04641676</a>)<a href="#bib2" class="usa-link" aria-describedby="bib2"><sup>2</sup></a> was a prospective tumor-agnostic effort of comprehensive NGS in patients with advanced cancers. In the study report of every patient, it was mentioned if a mutation was present that could be targeted with olaparib. Patients with a possible germline mutation on somatic NGS were referred for germline genetic testing. All mutations were monoallelic and only one class 4-5 variant in one of the HRR genes was present in every patient. Patients with a germline mutation carry this mutation in every tissue, the tumor cells included. A somatic mutation describes an alteration that is only present at the cellular level in somatic tissue occurring after fertilization.</p>
<p id="p0060">Advanced cancer patients (stage IV, metastatic disease) with a germline mutation or a somatic tumor mutation (class 1, benign and class 2, possibly benign variants were excluded) in the list of the HR genes mentioned previously were eligible for the study. There were no restrictions regarding the number of lines of treatment for study participation. Patients with ovarian cancer harboring an HRD gene mutation and breast cancer patients who harbor a <em>BRCA1</em> or <em>BRCA2</em> mutation were excluded because they had approved or clinical trial access to olaparib.</p></section><section id="sec2.2"><h3 class="pmc_sec_title">Study treatment and assessment</h3>
<p id="p0065">All patients with an HRD mutation were treated with olaparib in an open-label study. Study medication was available as a film-coated tablet containing olaparib 150 mg or 100 mg. Every patient started with a dose of 300 mg b.i.d. continually. Two dose reductions were allowed for toxicity reasons, a first reduction to 250 mg twice daily and a second to 200 mg twice daily.</p>
<p id="p0070">During the study, visits were carried out after 2 and 4 weeks, then every month and at the end of treatment. A computed tomography scan to evaluate response based on RECIST 1.1 was scheduled every 2 months and every 3 months after 1 year of treatment.</p></section><section id="sec2.3"><h3 class="pmc_sec_title">Statistical analysis</h3>
<p id="p0075">A cohort was defined by patients who harbor a somatic or germline mutation in the same gene. For each cohort, a Simon minimax two-stage design was used. In the first stage, 13 patients were accrued in each cohort. Only if a response was observed, 14 additional patients were accrued to a total of 27 in the second stage. The null hypothesis that the true response rate is 5% was tested against a one-sided alternative that the true response is 20%. The null hypothesis is rejected if three or more responses are observed in 27 patients. This design yields a type I error rate of 5% and a power of 80% when the true response rate is 20%. Further investigation is warranted if four or more responses are observed among the 27 subjects.</p>
<p id="p0080">In many rare gene cohorts, only signals of activity might be detected. These data will be reported later as case histories or small case series with descriptive statistics.</p></section></section><section id="sec3"><h2 class="pmc_sec_title">Results</h2>
<p id="p0085">A data lock was carried out on 28 October 2022. The median follow-up at that time was 24.5 months. An analysis has been executed for the completed cohorts: <em>ATM</em>, <em>BRCA1</em>, <em>BRCA2</em> and <em>CHEK2</em>.</p>
<section id="sec3.1"><h3 class="pmc_sec_title">Safety</h3>
<p id="p0090">Concerning safety, all patients included at the time of the data lock, 148 in total, were taken into account, not just those in the four complete cohorts. All safety observations were as known in the safety profile of olaparib, and the most prevalent are included in <a href="#tbl1" class="usa-link">Table 1</a>. Ninety-three (62%) of the patients experienced side-effects. In general, side-effects were mild (grades 1 and 2). Only 12 patients (8.11%) experienced a grade 3 event, and 1 (1.69%) experienced a grade 4 event. A notable high-grade event was an allergic reaction. About 30 min after taking the first dose of olaparib, the patient developed extreme facial flushing, shortness of breath and diffuse pruritus. Acute symptoms normalized after administering levocetirizine 5 mg and methylprednisolone 40 mg; cutaneous symptoms resolved after 24 h. The drug was permanently discontinued, although desensitization has been reported.<a href="#bib13" class="usa-link" aria-describedby="bib13"><sup>13</sup></a> The most common side-effects observed were nausea (40.68%), fatigue (33.89%), anorexia (25.41%), anemia (23.27%), vomiting (13.55%) and thrombocytopenia (11.68%). <a href="#appsec1" class="usa-link">Supplementary Table S1</a>, available at <a href="https://doi.org/10.1016/j.esmoop.2023.102041" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1016/j.esmoop.2023.102041</a>, displays the adverse events.</p>
<section class="tw xbox font-sm" id="tbl1"><h4 class="obj_head">Table 1.</h4>
<div class="caption p"><p>Clinical characteristics of patients in the BRCA1 cohort</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th colspan="1" rowspan="1">Patient number</th>
<th colspan="1" rowspan="1">Sex</th>
<th colspan="1" rowspan="1">Race</th>
<th colspan="1" rowspan="1">Germline mutation</th>
<th colspan="1" rowspan="1">Mutation</th>
<th colspan="1" rowspan="1">Organ or system of origin</th>
<th colspan="1" rowspan="1">Histology</th>
</tr></thead>
<tbody>
<tr>
<td colspan="1" rowspan="1">106</td>
<td colspan="1" rowspan="1">M</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_007249.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_007249.3</a> (BRCA1): c.2197_2201del</td>
<td colspan="1" rowspan="1">Pancreas</td>
<td colspan="1" rowspan="1">Adenocarcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">107</td>
<td colspan="1" rowspan="1">M</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_007294.3</a> (BRCA1): c.5309G&gt;T</td>
<td colspan="1" rowspan="1">Pancreas</td>
<td colspan="1" rowspan="1">Adenocarcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">110</td>
<td colspan="1" rowspan="1">F</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">No</td>
<td colspan="1" rowspan="1">BRCA1 inversion exon 3 (Foundation One)</td>
<td colspan="1" rowspan="1">Gallbladder</td>
<td colspan="1" rowspan="1">Adenocarcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">113</td>
<td colspan="1" rowspan="1">M</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">No</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_007294.3</a> (BRCA1): c.4484+1G&gt;A</td>
<td colspan="1" rowspan="1">Skin</td>
<td colspan="1" rowspan="1">Squamous carcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">117</td>
<td colspan="1" rowspan="1">F</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">No</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_007294.3</a> (BRCA1): c.1326T&gt;A</td>
<td colspan="1" rowspan="1">Uterus</td>
<td colspan="1" rowspan="1">Adenocarcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">216</td>
<td colspan="1" rowspan="1">M</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">No</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_007294.3</a> (BRCA1): c.5278-1G&gt;A</td>
<td colspan="1" rowspan="1">Bladder</td>
<td colspan="1" rowspan="1">Adenocarcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">225</td>
<td colspan="1" rowspan="1">F</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">No</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_007294.3</a> (BRCA1): c.2507_2508del</td>
<td colspan="1" rowspan="1">Pancreas</td>
<td colspan="1" rowspan="1">Adenocarcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">304</td>
<td colspan="1" rowspan="1">M</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_007294.3</a> (BRCA1): c.694G&gt;A</td>
<td colspan="1" rowspan="1">Pancreas</td>
<td colspan="1" rowspan="1">Adenocarcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">311</td>
<td colspan="1" rowspan="1">M</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">No</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_007294.3</a> (BRCA1): c.181T&gt;G</td>
<td colspan="1" rowspan="1">Skin</td>
<td colspan="1" rowspan="1">Carcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">315</td>
<td colspan="1" rowspan="1">F</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">No</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_007294.3</a> (BRCA1): c.1314_1315delGGinsAA</td>
<td colspan="1" rowspan="1">Pancreas</td>
<td colspan="1" rowspan="1">Adenocarcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">316</td>
<td colspan="1" rowspan="1">M</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_007294.3</a> (BRCA1): c.3841C&gt;T</td>
<td colspan="1" rowspan="1">Colon</td>
<td colspan="1" rowspan="1">Adenocarcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">317</td>
<td colspan="1" rowspan="1">F</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_007294.3</a> (BRCA1): c.3756_3759del</td>
<td colspan="1" rowspan="1">Rectum</td>
<td colspan="1" rowspan="1">Adenocarcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">318</td>
<td colspan="1" rowspan="1">M</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">No</td>
<td colspan="1" rowspan="1">NM 007294.3 (BRCA1): c.4099G&gt;T</td>
<td colspan="1" rowspan="1">Biliary tract</td>
<td colspan="1" rowspan="1">Adenocarcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">404</td>
<td colspan="1" rowspan="1">M</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">No</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_007294.3</a> (BRCA1): c.5266dup</td>
<td colspan="1" rowspan="1">Gallbladder</td>
<td colspan="1" rowspan="1">Adenocarcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">512</td>
<td colspan="1" rowspan="1">M</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">No</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_007294.3</a> (BRCA1): c.68_69de1AG</td>
<td colspan="1" rowspan="1">Stomach</td>
<td colspan="1" rowspan="1">Adenocarcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">513</td>
<td colspan="1" rowspan="1">M</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">No</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_007294.3</a> (BRCA1): c.3931_3934delAACA</td>
<td colspan="1" rowspan="1">Bladder</td>
<td colspan="1" rowspan="1">Carcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">608</td>
<td colspan="1" rowspan="1">M</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">No</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_007294.3</a> (BRCA1): c.2722G&gt;T</td>
<td colspan="1" rowspan="1">Liver</td>
<td colspan="1" rowspan="1">Carcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">704</td>
<td colspan="1" rowspan="1">M</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">No</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_007294.3</a> (BRCA1): c.212+1G&gt;T</td>
<td colspan="1" rowspan="1">Gallbladder</td>
<td colspan="1" rowspan="1">Adenocarcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">706</td>
<td colspan="1" rowspan="1">M</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_007294.3</a> (BRCA1): c.1016delA</td>
<td colspan="1" rowspan="1">Pancreas</td>
<td colspan="1" rowspan="1">Adenocarcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">711</td>
<td colspan="1" rowspan="1">F</td>
<td colspan="1" rowspan="1">A</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_007294.3</a> (BRCA1): c.981_982del</td>
<td colspan="1" rowspan="1">Pancreas</td>
<td colspan="1" rowspan="1">Adenocarcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">714</td>
<td colspan="1" rowspan="1">M</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">No</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_007294.3</a> (BRCA1): c.2359dup</td>
<td colspan="1" rowspan="1">Gallbladder</td>
<td colspan="1" rowspan="1">Adenocarcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">717</td>
<td colspan="1" rowspan="1">M</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">No</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_007294.3</a> (BRCA1): c.116G&gt;A</td>
<td colspan="1" rowspan="1">Pancreas</td>
<td colspan="1" rowspan="1">Adenocarcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">726</td>
<td colspan="1" rowspan="1">F</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_007294.3</a> (BRCA1): c.116G&gt;A</td>
<td colspan="1" rowspan="1">Pancreas</td>
<td colspan="1" rowspan="1">Adenocarcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">731</td>
<td colspan="1" rowspan="1">M</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_007294.3</a> (BRCA1): c.4987-1G&gt;T</td>
<td colspan="1" rowspan="1">Gallbladder</td>
<td colspan="1" rowspan="1">Adenocarcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">734</td>
<td colspan="1" rowspan="1">M</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">No</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_007294.3</a> (BRCA1): c.4987-1G&gt;T</td>
<td colspan="1" rowspan="1">Unknown primary</td>
<td colspan="1" rowspan="1">Neuroendocrine carcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">742</td>
<td colspan="1" rowspan="1">M</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">yes</td>
<td colspan="1" rowspan="1">NM_00724.3 (BRCA1): c.2359dup</td>
<td colspan="1" rowspan="1">Gallbladder</td>
<td colspan="1" rowspan="1">Adenocarcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">1107</td>
<td colspan="1" rowspan="1">M</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_007294.3</a> (BRCA1): c.1390del</td>
<td colspan="1" rowspan="1">Soft tissue</td>
<td colspan="1" rowspan="1">Sarcoma</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/tbl1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="fn1"><p>A, African; C, Caucasian; M, male; F, female.</p></div></div></section></section><section id="sec3.2"><h3 class="pmc_sec_title">Efficacy</h3>
<section id="sec3.2.1"><h4 class="pmc_sec_title">ATM cohort</h4>
<p id="p0095">Germline and somatic pathogenic and likely pathogenic mutations were found in various cancer types (<a href="#appsec1" class="usa-link">Supplementary Table S2</a>, available at <a href="https://doi.org/10.1016/j.esmoop.2023.102041" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1016/j.esmoop.2023.102041</a>).</p>
<p id="p0100">One partial response (PR) with a short duration was seen in a patient with squamous cell carcinoma of the esophagus (patient 720). The mutation in <em>ATM</em> is a frameshift mutation (p.Ser571Glufs∗11) that has never been reported. This 49-year-old patient was highly pretreated.</p>
<p id="p0105">In all other patients, immediate progressive disease was noted on the first evaluation after 2 months of treatment, illustrating the generally late-stage and aggressive nature of the disease in the patients included.</p>
<p id="p0110">The response to treatment with olaparib in the <em>ATM</em> cohort is shown in <a href="#appsec1" class="usa-link">Supplementary Figure S1</a>, available at <a href="https://doi.org/10.1016/j.esmoop.2023.102041" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1016/j.esmoop.2023.102041</a>.</p></section><section id="sec3.2.2"><h4 class="pmc_sec_title">BRCA1 cohort</h4>
<p id="p0115">Germline and somatic pathogenic and likely pathogenic mutations were found in various cancer types (<a href="#tbl1" class="usa-link">Table 1</a>).</p>
<p id="p0120">The response to therapy with olaparib in the <em>BRCA1</em> cohort is illustrated in <a href="#fig1" class="usa-link">Figure 1</a>.</p>
<figure class="fig xbox font-sm" id="fig1"><h5 class="obj_head">Figure 1.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10774963_gr1.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7853/10774963/e0da17bccd29/gr1.jpg" loading="lazy" height="730" width="748" alt="Figure 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/fig1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p><strong>Swimmer plot shows the response to treatment with olaparib in the BRCA1 cohort.</strong><em>x</em>-axis: time in months, <em>y</em>-axis: patient identification number. The events in time are displayed on the bar with each patient: complete response (filled black square), partial response (filled black triangle), stable disease (filled black circle) and progressive disease (empty circle). If an arrow is shown at the end of a bar, the response is still ongoing at the time of analysis.</p></figcaption></figure><p id="p0125">This cohort went to the second stage as a response was observed in the first stage. In our study no difference was seen in the response between germline and somatic mutation carriers. Three patients showed a PR. Two were diagnosed with pancreatic cancer (315, somatic protein-truncating mutation<a href="#bib14" class="usa-link" aria-describedby="bib14"><sup>14</sup></a> and 706, protein-truncating germline mutation<a href="#bib14" class="usa-link" aria-describedby="bib14"><sup>14</sup></a>), and one patient had gallbladder cancer (704, somatic frameshift mutation). The pancreatic cancer patients will not be discussed in detail because there are more extensive studies available in this population<a href="#bib9" class="usa-link" aria-describedby="bib9"><sup>9</sup></a>. The patient with gallbladder cancer was highly pretreated when he entered the study. He had been through four lines of chemotherapy: cisplatin/gemcitabine, intraperitoneal cisplatin, FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) and FOLFOX. Physical examination was normal, Eastern Cooperative Oncology Group (ECOG) 1 and the only abnormal value in the blood draw was a hemoglobin level of 10 g/dl. His medical history showed arterial hypertension, hypercholesterolemia and a coronary bypass. At the first evaluation at 2 months of treatment with olaparib, he showed a PR, and at the time of data lock, 34 months after the start of the study, the response was still ongoing. A first dose reduction was carried out after 2 weeks of treatment due to a grade 2 thrombocytopenia, and a second dose reduction after 10 months due to a grade 3 neutropenia.</p>
<p id="p0130">Fourteen patients had stable disease (SD). The overall response rate (ORR) was 11%, and the clinical benefit rate (CBR) was 63%.</p>
<p id="p0135">In summary, the <em>BRCA1</em> cohort includes 9 patients with pancreatic cancer and 18 patients with other tumor types. As far as the size of the cohorts allows, the CBR appears to be similar between the two groups: 55.5% (2 PR and 3 SD) for the pancreatic cancer patients and 66.6% (1 PR and 11 SD) for the other cancer patients. The partial remission was in a patient with gallbladder cancer, out of six patients with this cancer included in the study.</p></section><section id="sec3.2.3"><h4 class="pmc_sec_title">BRCA2 cohort</h4>
<p id="p0140">Germline and somatic pathogenic and likely pathogenic mutations were found in various cancer types (<a href="#tbl2" class="usa-link">Table 2</a>).</p>
<section class="tw xbox font-sm" id="tbl2"><h5 class="obj_head">Table 2.</h5>
<div class="caption p"><p>Clinical characteristics of patients in the BRCA2 cohort</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th colspan="1" rowspan="1">Patient number</th>
<th colspan="1" rowspan="1">Sex</th>
<th colspan="1" rowspan="1">Race</th>
<th colspan="1" rowspan="1">Germline mutation</th>
<th colspan="1" rowspan="1">Mutation</th>
<th colspan="1" rowspan="1">Organ or system of origin</th>
<th colspan="1" rowspan="1">Histology</th>
</tr></thead>
<tbody>
<tr>
<td colspan="1" rowspan="1">104</td>
<td colspan="1" rowspan="1">M</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">Deletion exon 19 (Foundation One)</td>
<td colspan="1" rowspan="1">Gallbladder</td>
<td colspan="1" rowspan="1">Adenocarcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">111</td>
<td colspan="1" rowspan="1">F</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_000059.4</a> (BRCA2): c.4935del</td>
<td colspan="1" rowspan="1">Colon</td>
<td colspan="1" rowspan="1">Adenocarcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">112</td>
<td colspan="1" rowspan="1">M</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">No</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_000059.3</a> (BRCA2): c.3751dup</td>
<td colspan="1" rowspan="1">Parathyroid</td>
<td colspan="1" rowspan="1">Carcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">118</td>
<td colspan="1" rowspan="1">M</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">No</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_000059.4</a> (BRCA2): c.8243G&gt;A</td>
<td colspan="1" rowspan="1">Gallbladder</td>
<td colspan="1" rowspan="1">Adenocarcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">122</td>
<td colspan="1" rowspan="1">M</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_000059.4</a> (BRCA2): c.8414_8416delinsC</td>
<td colspan="1" rowspan="1">Thyroid</td>
<td colspan="1" rowspan="1">Carcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">201</td>
<td colspan="1" rowspan="1">M</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_000059.3</a> (BRCA2): c.4936_4939del</td>
<td colspan="1" rowspan="1">Bladder</td>
<td colspan="1" rowspan="1">Adenocarcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">202</td>
<td colspan="1" rowspan="1">M</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_000059.3</a> (BRCA2): c.516+1G&gt;A</td>
<td colspan="1" rowspan="1">Colon</td>
<td colspan="1" rowspan="1">Adenocarcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">205</td>
<td colspan="1" rowspan="1">F</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_000059.3</a> (BRCA2): c.6503-6504delTT</td>
<td colspan="1" rowspan="1">Cervical</td>
<td colspan="1" rowspan="1">Squamous carcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">302</td>
<td colspan="1" rowspan="1">M</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_000059.3</a> (BRCA2): c.4472_4475del</td>
<td colspan="1" rowspan="1">Pancreas</td>
<td colspan="1" rowspan="1">Adenocarcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">401</td>
<td colspan="1" rowspan="1">F</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">No</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_000059.3</a> (BRCA2): c.9709delA</td>
<td colspan="1" rowspan="1">Genito-uretral</td>
<td colspan="1" rowspan="1">Adenocarcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">402</td>
<td colspan="1" rowspan="1">F</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">No</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_000059.3</a> (BRCA2): c.2175dupA</td>
<td colspan="1" rowspan="1">Pancreas</td>
<td colspan="1" rowspan="1">Adenocarcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">403</td>
<td colspan="1" rowspan="1">M</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">No</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_000059.3</a> (BRCA2): c.2588delIA</td>
<td colspan="1" rowspan="1">Lung</td>
<td colspan="1" rowspan="1">Adenocarcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">511</td>
<td colspan="1" rowspan="1">F</td>
<td colspan="1" rowspan="1">A</td>
<td colspan="1" rowspan="1">No</td>
<td colspan="1" rowspan="1">Rearrangement exon 10 (Foundation One)</td>
<td colspan="1" rowspan="1">Paraganglion</td>
<td colspan="1" rowspan="1">Paraganglioma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">601</td>
<td colspan="1" rowspan="1">F</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_000059.3</a> (BRCA2): c.516+1G&gt;A</td>
<td colspan="1" rowspan="1">Pancreas</td>
<td colspan="1" rowspan="1">Adenocarcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">602</td>
<td colspan="1" rowspan="1">M</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_000059.3</a> (BRCA2): c.4602delT</td>
<td colspan="1" rowspan="1">Pancreas</td>
<td colspan="1" rowspan="1">Adenocarcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">702</td>
<td colspan="1" rowspan="1">M</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_000059.3</a> (BRCA2): c.5936del</td>
<td colspan="1" rowspan="1">Pancreas</td>
<td colspan="1" rowspan="1">Adenocarcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">705</td>
<td colspan="1" rowspan="1">M</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_000059.3</a> (BRCA2): c.5682C&gt;G</td>
<td colspan="1" rowspan="1">Pancreas</td>
<td colspan="1" rowspan="1">Adenocarcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">708</td>
<td colspan="1" rowspan="1">M</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_000059.3</a> (BRCA2): c.5213_5216del</td>
<td colspan="1" rowspan="1">Pancreas</td>
<td colspan="1" rowspan="1">Adenocarcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">713</td>
<td colspan="1" rowspan="1">M</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">No</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_000059.3</a> (BRCA2): 6503-6504delTT</td>
<td colspan="1" rowspan="1">Pancreas</td>
<td colspan="1" rowspan="1">Neuroendocrine carcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">716</td>
<td colspan="1" rowspan="1">M</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">No</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_000059.3</a> (BRCA2): c.6600_6601del</td>
<td colspan="1" rowspan="1">Pancreas</td>
<td colspan="1" rowspan="1">Adenocarcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">724</td>
<td colspan="1" rowspan="1">M</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_000059.3</a> (BRCA2): c.7544del</td>
<td colspan="1" rowspan="1">Pancreas</td>
<td colspan="1" rowspan="1">Adenocarcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">727</td>
<td colspan="1" rowspan="1">M</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_000059.3</a> (BRCA2): c.6270_6271del</td>
<td colspan="1" rowspan="1">Colon</td>
<td colspan="1" rowspan="1">Adenocarcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">729</td>
<td colspan="1" rowspan="1">M</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_000059.3</a> (BRCA2): c.5946del</td>
<td colspan="1" rowspan="1">Stomach</td>
<td colspan="1" rowspan="1">Adenocarcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">733</td>
<td colspan="1" rowspan="1">F</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_000059.3</a> (BRCA2): c.5213_5216del</td>
<td colspan="1" rowspan="1">Pancreas</td>
<td colspan="1" rowspan="1">Adenocarcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">735</td>
<td colspan="1" rowspan="1">M</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_000059.3</a> (BRCA2): c.3847_3848del</td>
<td colspan="1" rowspan="1">Gallbladder</td>
<td colspan="1" rowspan="1">Adenocarcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">736</td>
<td colspan="1" rowspan="1">M</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_000059.3</a> (BRCA2): c.9117G&gt;A</td>
<td colspan="1" rowspan="1">Pancreas</td>
<td colspan="1" rowspan="1">Adenocarcinoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">1108</td>
<td colspan="1" rowspan="1">M</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">No</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_000059.3</a> (BRCA2): c.3860del</td>
<td colspan="1" rowspan="1">Soft tissue</td>
<td colspan="1" rowspan="1">Sarcoma</td>
</tr>
<tr>
<td colspan="1" rowspan="1">1201</td>
<td colspan="1" rowspan="1">M</td>
<td colspan="1" rowspan="1">C</td>
<td colspan="1" rowspan="1">No</td>
<td colspan="1" rowspan="1">
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.3" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NM_000059.3</a> (BRCA2): c.6275_6276del</td>
<td colspan="1" rowspan="1">Head and neck</td>
<td colspan="1" rowspan="1">Squamous carcinoma</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/tbl2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="fn2"><p>A, African; C, Caucasian; M, male; F, female.</p></div></div></section><p id="p0145">The response to treatment with olaparib in the <em>BRCA2</em> cohort is shown in <a href="#fig2" class="usa-link">Figure 2</a>.</p>
<figure class="fig xbox font-sm" id="fig2"><h5 class="obj_head">Figure 2.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10774963_gr2.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7853/10774963/7328b87034ae/gr2.jpg" loading="lazy" height="754" width="764" alt="Figure 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/fig2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p><strong>Swimmer plot shows the response to treatment with olaparib in the BRCA2 cohort.</strong><em>x</em>-axis: time in months, <em>y</em>-axis: patient identification number. The events in time are displayed on the bar with each patient: complete response (filled black square), partial response (filled black triangle), stable disease (filled black circle) and progressive disease (empty circle). If an arrow is shown at the end of a bar, the response is still ongoing at the time of analysis.</p></figcaption></figure><p id="p0150">Responses were seen in both somatic and germline mutation carriers. Five patients achieved a PR, and one patient a complete response (CR), or a response rate of 22%. Three of the partial responders had pancreatic adenocarcinomas (601, a mutation causing a splicing error; 724, germline mutation; 716, a protein-truncating somatic mutation), one patient with pancreatic neuroendocrine carcinoma (713, somatic frameshift mutation) and one patient with parathyroid carcinoma (112, somatic frameshift mutation). Since olaparib is registered and reimbursed in patients with pancreatic adenocarcinoma carrying a germline <em>BRCA2</em> mutation, these cases will not be discussed in detail. It is important to emphasize that patient 716 carries a somatic <em>BRCA2</em> mutation (not eligible for reimbursed drug access) and experienced a PR. This patient had metastases in the right lung and the subcarinal lymph nodes. After 2 months, a PR was seen at all sites but at 6 months, re-evaluation demonstrated progressive disease. In patient 724, the disease was localized in the lungs and at the esophagogastric junction. The first scan, at 2 months, revealed a PR and progressive disease at 4 months. The initial stage of the neuroendocrine carcinoma of the pancreas was pT4N1, for which the patient underwent a left hemi-pancreatectomy with a wedge resection of the stomach. Ten years later, the patient developed a recurrence in the abdominal lymph nodes for which carboplatin-etoposide was given as first-line chemotherapy followed by progression and FOLFOX as second-line chemotherapy. The patient’s medical history notes a pT1cN0M0 invasive ductal carcinoma of the left breast and type II diabetes mellitus. At study entry, the metastatic sites were the inguinal lymph nodes and the iliac bone. Six months after initiating therapy with olaparib, a PR was seen at all disease sites and was still ongoing at 28 months (= data cut-off). No dose reductions were required. The patient with parathyroid carcinoma was a 32-year-old, healthy Caucasian male who had undergone multiple surgeries (total thyroidectomy and central neck exploration, parathyroidectomy, partial sternotomy, mediastinal metastasectomy, bilateral cervical gland exploration) and radiotherapy (total dose of 70 Gy in 35 fractions). The physical examination was normal at inclusion and ECOG 0. The disease was localized in the lung and sternum. After 1 month, a dose reduction to 500 mg was carried out due to grade 2 nausea that did not improve with dietary changes, anti-emetic drugs and proton pump inhibitors. At 10 months, a PR was seen in all metastatic spots and was still ongoing after 20 months, the moment of data cut-off.</p>
<p id="p0155">One patient with colon cancer achieved a CR (727, germline frameshift mutation). The patient had an impressive oncological history: diagnosed at the age of 59 years with an adenocarcinoma of the stomach, invasive ductal carcinoma of the breast when he was 63 years old and diagnosed at the age of 67 years with a pT3N0M0 adenocarcinoma of the colon. Nine years later, he had a relapse of the adenocarcinoma of the colon (histologically confirmed diagnosis) for which FOLFOX chemotherapy was started. At study entry, the disease was restricted to the ileocolic anastomosis. After 2 months on treatment with olaparib, a PR was seen, and a CR after 12 months. After 19 months (data cut-off), the CR was ongoing, and no dose adjustments were required.</p>
<p id="p0160">Seven patients showed an SD. The ORR in this cohort is 22% and the CBR 51%.</p>
<p id="p0165">In summary, the <em>BRCA2</em> cohort consists of 11 patients with adenocarcinoma of the pancreas and 16 patients with other tumor histology. The CBR is also similar between the two groups: 54.5% (three PR, three SD) and 43.8% (one CR, two PR and four SD). The responders were diagnosed with colon cancer, parathyroid carcinoma and pancreatic neuroendocrine carcinoma. In this cohort, three patients with colon cancer were included and only one patient with parathyroid or pancreatic neuroendocrine carcinoma.</p></section><section id="sec3.2.4"><h4 class="pmc_sec_title">CHEK2 cohort</h4>
<p id="p0170">Germline and somatic pathogenic and likely pathogenic mutations were found in various cancer types (<a href="#appsec1" class="usa-link">Supplementary Table S3</a>, available at <a href="https://doi.org/10.1016/j.esmoop.2023.102041" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1016/j.esmoop.2023.102041</a>).</p>
<p id="p0175">The response to therapy with olaparib in the <em>CHEK2</em> cohort is illustrated in <a href="#appsec1" class="usa-link">Supplementary Figure S2</a>, available at <a href="https://doi.org/10.1016/j.esmoop.2023.102041" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1016/j.esmoop.2023.102041</a>.</p>
<p id="p0180">No clinical benefit was seen in most patients, although two patients had SD for several months. Patient 121, a female with an extensively pretreated stage IV melanoma, had SD for 2 months. Patient 306, a female with stage IV breast cancer with only hormonal pretreatment, experienced SD for 11 months.</p></section></section></section><section id="sec4"><h2 class="pmc_sec_title">Discussion</h2>
<p id="p0185">We report the clinical activity of olaparib in advanced cancers that carry a <em>BRCA1/2</em>, <em>CHEK2</em> or <em>ATM</em> mutation. These are completed cohorts of a tumor-agnostic Belgian basket phase II trial that investigates the clinical activity of olaparib in cancers with a somatic or germline mutation in genes that play a role in HR. PARP inhibition might be active in cancers with an HRD caused by other gene mutations or cancer types than currently documented or approved.</p>
<p id="p0190">At the time of study design, only BRCA mutation testing was an approved biomarker for PARPi use. In recent years, new methods to measure HRD have been developed.<a href="#bib15" class="usa-link" aria-describedby="bib15"><sup>15</sup></a> HRD testing may include the detection of tumor mutations in genes beyond <em>BRCA1</em>/<em>BRCA2</em> that are implicated in HRR (the approach used in this study) and genomic instability to evaluate the molecular phenotype of HRD beyond BRCA mutations. Currently, different methodologies and genomic markers are used in HRD testing.<a href="#bib16" class="usa-link" aria-describedby="bib16"><sup>16</sup></a> In future studies, the different methods must be integrated to predict response sensitivity to PARPi better.</p>
<p id="p0195">At the time of writing, the European Medicines Agency (EMA) approval for olaparib as monotherapy includes <em>BRCA1/2</em>-mutated ovarian, breast, prostate and pancreatic cancer.<a href="#bib17" class="usa-link" aria-describedby="bib17"><sup>17</sup></a> EMA also approved olaparib in combination with bevacizumab for the treatment of HRD-positive ovarian cancer patients and in combination with abiraterone for the treatment of HRR-mutated prostate cancer.</p>
<p id="p0200">No novel safety signals were observed besides those included in the product information.<a href="#bib18" class="usa-link" aria-describedby="bib18"><sup>18</sup></a><sup>,</sup><a href="#bib19" class="usa-link" aria-describedby="bib19"><sup>19</sup></a> We had one patient with a rare allergy to olaparib leading to discontinuation of the treatment, although desensitization and subsequent continuation of olaparib would be possible.<a href="#bib13" class="usa-link" aria-describedby="bib13"><sup>13</sup></a></p>
<p id="p0205">This study observed no clinically relevant activity in patients with an <em>ATM</em> mutation. The literature shows conflicting data concerning <em>ATM</em>-mutated cancer and response to PARPi. The Profound study<a href="#bib20" class="usa-link" aria-describedby="bib20"><sup>20</sup></a> showed a benefit of olaparib in prostate cancers harboring an <em>ATM</em>, <em>BRCA1</em> or <em>BRCA2</em> mutation. In a study with talazoparib and avelumab in patients with <em>BRCA1/2-</em> or <em>ATM</em>-mutated advanced tumor types (JAVELIN trial), recruitment in the <em>ATM</em> cohort was terminated early because the ORR was 10.5% (two responses in unspecified tumor types).<a href="#bib21" class="usa-link" aria-describedby="bib21"><sup>21</sup></a> One report describes a patient with a small-cell <em>ATM</em>-mutated esophageal cancer who had a response for 5.9 months with the addition of olaparib to etoposide.<a href="#bib22" class="usa-link" aria-describedby="bib22"><sup>22</sup></a>. The preclinical evidence of PARPi in <em>ATM</em>-mutated cancers is conflicting. <em>ATM</em>-mutated prostate cancer was not sensitive to PARPi but sensitive to <em>ATR</em> inhibition.<a href="#bib23" class="usa-link" aria-describedby="bib23"><sup>23</sup></a><sup>,</sup><a href="#bib24" class="usa-link" aria-describedby="bib24"><sup>24</sup></a> PARPi can be active in the presence of homozygous kinase-dead mutations in the <em>ATM</em> gene,<a href="#bib23" class="usa-link" aria-describedby="bib23"><sup>23</sup></a> consistent with sensitization to PARPi when <em>ATM</em> is experimentally depleted.<a href="#bib25" class="usa-link" aria-describedby="bib25"><sup>25</sup></a></p>
<p id="p0210">No response was also seen in the <em>CHEK2</em> mutation cohort. A phase II study in patients with CHEK2-mutated advanced breast cancer also failed to find olaparib activity.<a href="#bib26" class="usa-link" aria-describedby="bib26"><sup>26</sup></a></p>
<p id="p0215">In contrast, in the <em>BRCA1/2</em>-mutated cancers, treatment with olaparib is effective. Before the start of this study, olaparib had already been approved and reimbursed as a treatment for patients with BRCA-mutated ovarian cancer (SOLO-1 trial)<a href="#bib5" class="usa-link" aria-describedby="bib5"><sup>5</sup></a><sup>,</sup><a href="#bib27" class="usa-link" aria-describedby="bib27"><sup>27</sup></a> and breast cancer (OlympiAD trial<a href="#bib28" class="usa-link" aria-describedby="bib28"><sup>28</sup></a>). Studies in ovarian cancer patients with an HRD were ongoing (e.g. PAOLA-1 trial, olaparib in combination with bevacizumab<a href="#bib29" class="usa-link" aria-describedby="bib29"><sup>29</sup></a>). As a result, these patient populations were not eligible for the current study.</p>
<p id="p0220">The response rate in <em>BRCA1</em>-mutated cancers was modest (11%) and observed in two pancreatic and one gall bladder cancer cases. The responsiveness of <em>BRCA1/2</em>-mutated pancreatic cancer to PARPi has, since the initiation of our study, been solidly documented, leading to regulatory approval of olaparib in this indication.<a href="#bib30" class="usa-link" aria-describedby="bib30">30</a>, <a href="#bib31" class="usa-link" aria-describedby="bib31">31</a>, <a href="#bib32" class="usa-link" aria-describedby="bib32">32</a></p>
<p id="p0225">The extended response (34+ months) to olaparib in a gallbladder adenocarcinoma with a <em>BRCA1</em> mutation is an index case, consistent with the fact that <em>BRCA1/2</em> mutations predispose to biliary tract cancer, supporting a strong driver role.<a href="#bib33" class="usa-link" aria-describedby="bib33"><sup>33</sup></a>
<em>BRCA2</em> mutations are more prevalent (3%) in biliary tract cancers than <em>BRCA1</em> (0.6%), and several cases of response to PARPi have been reported in <em>BRCA2</em>-mutated biliary tract cancer.<a href="#bib33" class="usa-link" aria-describedby="bib33"><sup>33</sup></a></p>
<p id="p0230">We also observed a prolonged, slowly achieved response to olaparib in a somatic <em>BRCA2</em>-mutated parathyroid carcinoma with an 18-month ongoing PR. Parathyroid cancer is a very rare cancer (0.005% of all malignancies). This index case is an extreme example of the clinical utility of agnostic sequencing in any cancer type, as neither <em>BRCA1/2</em> mutations nor responses to olaparib have ever been reported before in this cancer type. And this is even more valid in rare cancers lacking effective therapies. The important response supports a driver function for <em>BRCA2</em> in parathyroid cancer.</p>
<p id="p0235">A patient with a <em>BRCA2</em>-mutated adenocarcinoma of the colon, an index case, also slowly developed a long-term complete and ongoing remission. <em>BRCA1/2</em> mutation carriers have a possible modest increase in colorectal cancer risk.<a href="#bib34" class="usa-link" aria-describedby="bib34"><sup>34</sup></a> However, no prior reports of PARPi response in <em>BRCA2</em>-mutant colorectal cancer exist. Preclinical studies have found that a small proportion of colorectal cancer cell lines are sensitive to olaparib when <em>TP53</em> is mutated but without an HRD.<a href="#bib35" class="usa-link" aria-describedby="bib35"><sup>35</sup></a> One patient with <em>CHEK2</em>-mutated metastatic colorectal cancer was reported to respond to olaparib.<a href="#bib36" class="usa-link" aria-describedby="bib36"><sup>36</sup></a> A more recent publication in colon cancer organoids revealed preclinical activity of olaparib in a <em>BRCA2</em>-mutated colorectal cancer, but the patient could not be treated to confirm this activity.<a href="#bib37" class="usa-link" aria-describedby="bib37"><sup>37</sup></a> A prospective phase II study specifically in <em>BRCA1/2</em>-mutated colorectal cancer seems warranted.</p>
<p id="p0240">A last important remark is the fact that most patients in this study are highly pretreated (median therapeutic lines in metastatic setting is 2). The phase III SOLO-1<a href="#bib27" class="usa-link" aria-describedby="bib27"><sup>27</sup></a> (maintenance olaparib after first-line platinum-based chemotherapy) and SOLO-3 trials<a href="#bib38" class="usa-link" aria-describedby="bib38"><sup>38</sup></a> (olaparib monotherapy in third line) in advanced BRCA-mutated ovarian cancer taught us that the early introduction of olaparib offers the most significant benefit. Patient 112, diagnosed with parathyroid carcinomas with a somatic <em>BRCA2</em> mutation, is one of the patients who supports this in the current study. This patient was never previously exposed to systemic treatment and shows a sustained response.<a href="#bib39" class="usa-link" aria-describedby="bib39"><sup>39</sup></a></p>
<p id="p0245">Our study results are in favor of the utility of tumor-agnostic NGS in all cancer types. Without agnostic NGS, the patients who benefited from the treatment in our study would not have had access to the treatment. These data and data from additional cohorts could, hopefully, move regulators and health insurers to allow implementation of broad agnostic NGS and corresponding drug access in clinical practice. It would be very difficult to accrue enough patients with rare cancer type–genotype associations in phase III trials.</p>
<section id="sec4.1"><h3 class="pmc_sec_title">Conclusion</h3>
<p id="p0250">In this study, olaparib does not have clinically meaningful activity in cancers with an <em>ATM</em> or <em>CHEK2</em> mutation.</p>
<p id="p0255">In <em>BRCA1/2</em>-mutated cancers, olaparib can be active and produce durable responses in various cancer types.</p></section></section><section id="sec5"><h2 class="pmc_sec_title">Funding</h2>
<p id="p0260">This work was supported by pharmaceutical companies AstraZeneca (global) and Merckx for medication supply and financial contributions. Financial support was provided by Kom op tegen Kanker (Stand up to Cancer), the Flemish Cancer Society (project ID: 1145) and the Stichting Tegen Kanker (no grant number).</p></section><section id="sec6"><h2 class="pmc_sec_title">Disclosure</h2>
<p id="p0265">The authors have declared no conflicts of interest.</p></section><section id="appsec1"><h2 class="pmc_sec_title">Supplementary data</h2>
<figure class="fig xbox font-sm" id="dfig1"><h3 class="obj_head">Supplementary Figure 1.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10774963_figs1.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7853/10774963/b0b45ef72f8c/figs1.jpg" loading="lazy" height="356" width="747" alt="Supplementary Figure 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/dfig1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></figure><figure class="fig xbox font-sm" id="dfig2"><h3 class="obj_head">Supplementary Figure 2.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10774963_figs2.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7853/10774963/13265a2e576f/figs2.jpg" loading="lazy" height="355" width="747" alt="Supplementary Figure 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/dfig2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></figure><section class="sm xbox font-sm" id="mmc3"><div class="caption p"><span>Supplementary Table</span></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/10774963/bin/mmc1.xlsx" data-ga-action="click_feat_suppl" class="usa-link">mmc1.xlsx</a><sup> (11.3KB, xlsx) </sup>
</div></div></section><section class="sm xbox font-sm" id="mmc4"><div class="caption p"><span>Supplementary Table</span></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/10774963/bin/mmc2.xlsx" data-ga-action="click_feat_suppl" class="usa-link">mmc2.xlsx</a><sup> (11.8KB, xlsx) </sup>
</div></div></section><section class="sm xbox font-sm" id="mmc5"><div class="caption p"><span>Supplementary Table</span></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/10774963/bin/mmc3.xlsx" data-ga-action="click_feat_suppl" class="usa-link">mmc3.xlsx</a><sup> (11.9KB, xlsx) </sup>
</div></div></section><section class="sm xbox font-sm" id="mmc6"><div class="caption p"><span>Supplementary Appendix 1</span></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/10774963/bin/mmc4.xlsx" data-ga-action="click_feat_suppl" class="usa-link">mmc4.xlsx</a><sup> (12.3KB, xlsx) </sup>
</div></div></section></section><section id="cebib0010" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="cebib0010_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="bib1">
<span class="label">1.</span><cite>Bailey M.H., Tokheim C., Porta-Pardo E., et al.  Comprehensive characterization of cancer driver genes and mutations. Cell. 2018;173(2):371–385.e18. doi: 10.1016/j.cell.2018.02.060.</cite> [<a href="https://doi.org/10.1016/j.cell.2018.02.060" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6029450/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29625053/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=Comprehensive%20characterization%20of%20cancer%20driver%20genes%20and%20mutations&amp;author=M.H.%20Bailey&amp;author=C.%20Tokheim&amp;author=E.%20Porta-Pardo&amp;volume=173&amp;issue=2&amp;publication_year=2018&amp;pages=371-385.e18&amp;pmid=29625053&amp;doi=10.1016/j.cell.2018.02.060&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib2">
<span class="label">2.</span><cite>Thouvenin J., Van Marcke C., Decoster L., et al.  PRECISION: the Belgian molecular profiling program of metastatic cancer for clinical decision and treatment assignment. ESMO Open. 2022;7(4) doi: 10.1016/j.esmoop.2022.100524.</cite> [<a href="https://doi.org/10.1016/j.esmoop.2022.100524" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9434164/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35970014/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=ESMO%20Open&amp;title=PRECISION:%20the%20Belgian%20molecular%20profiling%20program%20of%20metastatic%20cancer%20for%20clinical%20decision%20and%20treatment%20assignment&amp;author=J.%20Thouvenin&amp;author=C.%20Van%20Marcke&amp;author=L.%20Decoster&amp;volume=7&amp;issue=4&amp;publication_year=2022&amp;pmid=35970014&amp;doi=10.1016/j.esmoop.2022.100524&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib3">
<span class="label">3.</span><cite>Lopacinska-Joergensen J., Oliveira D., Poulsen T.S., Hoegdall C.K., Hoegdall E.V. Somatic variants in DNA damage response genes in ovarian cancer patients using whole-exome sequencing. Anticancer Res. 2023;43(5):1891–1900. doi: 10.21873/anticanres.16348.</cite> [<a href="https://doi.org/10.21873/anticanres.16348" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37097678/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Anticancer%20Res&amp;title=Somatic%20variants%20in%20DNA%20damage%20response%20genes%20in%20ovarian%20cancer%20patients%20using%20whole-exome%20sequencing&amp;author=J.%20Lopacinska-Joergensen&amp;author=D.%20Oliveira&amp;author=T.S.%20Poulsen&amp;author=C.K.%20Hoegdall&amp;author=E.V.%20Hoegdall&amp;volume=43&amp;issue=5&amp;publication_year=2023&amp;pages=1891-1900&amp;pmid=37097678&amp;doi=10.21873/anticanres.16348&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib4">
<span class="label">4.</span><cite>Dalmasso B., Puccini A., Catalano F., et al.  Beyond BRCA: the emerging significance of DNA damage response and personalized treatment in pancreatic and prostate cancer patients. Int J Mol Sci. 2022;23(9):4709. doi: 10.3390/ijms23094709.</cite> [<a href="https://doi.org/10.3390/ijms23094709" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9099822/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35563100/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Mol%20Sci&amp;title=Beyond%20BRCA:%20the%20emerging%20significance%20of%20DNA%20damage%20response%20and%20personalized%20treatment%20in%20pancreatic%20and%20prostate%20cancer%20patients&amp;author=B.%20Dalmasso&amp;author=A.%20Puccini&amp;author=F.%20Catalano&amp;volume=23&amp;issue=9&amp;publication_year=2022&amp;pages=4709&amp;pmid=35563100&amp;doi=10.3390/ijms23094709&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib5">
<span class="label">5.</span><cite>DiSilvestro P., Banerjee S., Colombo N., et al.  Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1/GOG 3004 trial. J Clin Oncol. 2023;41:609–617. doi: 10.1200/JCO.22.01549.</cite> [<a href="https://doi.org/10.1200/JCO.22.01549" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9870219/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36082969/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%C2%A0Clin%20Oncol&amp;title=Overall%20survival%20with%20maintenance%20olaparib%20at%20a%207-year%20follow-up%20in%20patients%20with%20newly%20diagnosed%20advanced%20ovarian%20cancer%20and%20a%20BRCA%20mutation:%20the%20SOLO1/GOG%203004%20trial&amp;author=P.%20DiSilvestro&amp;author=S.%20Banerjee&amp;author=N.%20Colombo&amp;volume=41&amp;publication_year=2023&amp;pages=609-617&amp;pmid=36082969&amp;doi=10.1200/JCO.22.01549&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib6">
<span class="label">6.</span><cite>Griguolo G., Dieci M.V., Miglietta F., Guarneri V., Conte P. Olaparib for advanced breast cancer. Future Oncol. 2020;16(12):717–732. doi: 10.2217/fon-2019-0689.</cite> [<a href="https://doi.org/10.2217/fon-2019-0689" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32249603/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Future%20Oncol&amp;title=Olaparib%20for%20advanced%20breast%20cancer&amp;author=G.%20Griguolo&amp;author=M.V.%20Dieci&amp;author=F.%20Miglietta&amp;author=V.%20Guarneri&amp;author=P.%20Conte&amp;volume=16&amp;issue=12&amp;publication_year=2020&amp;pages=717-732&amp;pmid=32249603&amp;doi=10.2217/fon-2019-0689&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib7">
<span class="label">7.</span><cite>Robson M., Im S.A., Senkus E., et al.  Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523–533. doi: 10.1056/NEJMoa1706450.</cite> [<a href="https://doi.org/10.1056/NEJMoa1706450" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28578601/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%C2%A0Engl%20J%20Med&amp;title=Olaparib%20for%20metastatic%20breast%20cancer%20in%20patients%20with%20a%20germline%20BRCA%20mutation&amp;author=M.%20Robson&amp;author=S.A.%20Im&amp;author=E.%20Senkus&amp;volume=377&amp;issue=6&amp;publication_year=2017&amp;pages=523-533&amp;pmid=28578601&amp;doi=10.1056/NEJMoa1706450&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib8">
<span class="label">8.</span><cite>Inderjeeth A.J., Topp M., Sanij E., Castro E., Sandhu S. Clinical application of poly(ADP-ribose) polymerase (PARP) inhibitors in prostate cancer. Cancers (Basel) 2022;14(23):5922. doi: 10.3390/cancers14235922.</cite> [<a href="https://doi.org/10.3390/cancers14235922" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9736565/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36497408/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers%20(Basel)&amp;title=Clinical%20application%20of%20poly(ADP-ribose)%20polymerase%20(PARP)%20inhibitors%20in%20prostate%20cancer&amp;author=A.J.%20Inderjeeth&amp;author=M.%20Topp&amp;author=E.%20Sanij&amp;author=E.%20Castro&amp;author=S.%20Sandhu&amp;volume=14&amp;issue=23&amp;publication_year=2022&amp;pages=5922&amp;pmid=36497408&amp;doi=10.3390/cancers14235922&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib9">
<span class="label">9.</span><cite>Golan T., Hammel P., Reni M., et al.  Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381(4):317–327. doi: 10.1056/NEJMoa1903387.</cite> [<a href="https://doi.org/10.1056/NEJMoa1903387" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6810605/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31157963/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%C2%A0Engl%20J%20Med&amp;title=Maintenance%20olaparib%20for%20germline%20BRCA-mutated%20metastatic%20pancreatic%20cancer&amp;author=T.%20Golan&amp;author=P.%20Hammel&amp;author=M.%20Reni&amp;volume=381&amp;issue=4&amp;publication_year=2019&amp;pages=317-327&amp;pmid=31157963&amp;doi=10.1056/NEJMoa1903387&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib10">
<span class="label">10.</span><cite>Walsh T., Casadei S., Lee M.K., et al.  Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A. 2011;108(44):18032–18037. doi: 10.1073/pnas.1115052108.</cite> [<a href="https://doi.org/10.1073/pnas.1115052108" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3207658/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22006311/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Proc%20Natl%20Acad%20Sci%20U%20S%20A&amp;title=Mutations%20in%2012%20genes%20for%20inherited%20ovarian,%20fallopian%20tube,%20and%20peritoneal%20carcinoma%20identified%20by%20massively%20parallel%20sequencing&amp;author=T.%20Walsh&amp;author=S.%20Casadei&amp;author=M.K.%20Lee&amp;volume=108&amp;issue=44&amp;publication_year=2011&amp;pages=18032-18037&amp;pmid=22006311&amp;doi=10.1073/pnas.1115052108&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib11">
<span class="label">11.</span><cite>De Brakeleer S., De Greve J., Desmedt C., et al.  Frequent incidence of BARD1-truncating mutations in germline DNA from triple-negative breast cancer patients. Clin Genet. 2016;89(3):336–340. doi: 10.1111/cge.12620.</cite> [<a href="https://doi.org/10.1111/cge.12620" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26010302/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Genet&amp;title=Frequent%20incidence%20of%20BARD1-truncating%20mutations%20in%20germline%20DNA%20from%20triple-negative%20breast%20cancer%20patients&amp;author=S.%20De%20Brakeleer&amp;author=J.%20De%20Greve&amp;author=C.%20Desmedt&amp;volume=89&amp;issue=3&amp;publication_year=2016&amp;pages=336-340&amp;pmid=26010302&amp;doi=10.1111/cge.12620&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib12">
<span class="label">12.</span><cite>Riaz N., Blecua P., Lim R.S., et al.  Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes. Nat Commun. 2017;8(1):857. doi: 10.1038/s41467-017-00921-w.</cite> [<a href="https://doi.org/10.1038/s41467-017-00921-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5636842/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29021619/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Commun&amp;title=Pan-cancer%20analysis%20of%20bi-allelic%20alterations%20in%20homologous%20recombination%20DNA%20repair%20genes&amp;author=N.%20Riaz&amp;author=P.%20Blecua&amp;author=R.S.%20Lim&amp;volume=8&amp;issue=1&amp;publication_year=2017&amp;pages=857&amp;pmid=29021619&amp;doi=10.1038/s41467-017-00921-w&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib13">
<span class="label">13.</span><cite>Grabowski J.P., Sehouli J., Glajzer J., et al.  Olaparib desensitization in a patient with recurrent peritoneal cancer. N Engl J Med. 2018;379(22):2176–2177. doi: 10.1056/NEJMc1810168.</cite> [<a href="https://doi.org/10.1056/NEJMc1810168" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30485775/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%C2%A0Engl%20J%20Med&amp;title=Olaparib%20desensitization%20in%20a%20patient%20with%20recurrent%20peritoneal%20cancer&amp;author=J.P.%20Grabowski&amp;author=J.%20Sehouli&amp;author=J.%20Glajzer&amp;volume=379&amp;issue=22&amp;publication_year=2018&amp;pages=2176-2177&amp;pmid=30485775&amp;doi=10.1056/NEJMc1810168&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib14">
<span class="label">14.</span><cite>Nykamp K., Anderson M., Powers M., et al.  Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria. Genet Med. 2017;19(10):1105–1117. doi: 10.1038/gim.2017.37.</cite> [<a href="https://doi.org/10.1038/gim.2017.37" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5632818/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28492532/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Genet%20Med&amp;title=Sherloc:%20a%20comprehensive%20refinement%20of%20the%20ACMG-AMP%20variant%20classification%20criteria&amp;author=K.%20Nykamp&amp;author=M.%20Anderson&amp;author=M.%20Powers&amp;volume=19&amp;issue=10&amp;publication_year=2017&amp;pages=1105-1117&amp;pmid=28492532&amp;doi=10.1038/gim.2017.37&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib15">
<span class="label">15.</span><cite>Hoppe M.M., Sundar R., Tan D.S.P., Jeyasekharan A.D. Biomarkers for homologous recombination deficiency in cancer. J Natl Cancer Inst. 2018;110(7):704–713. doi: 10.1093/jnci/djy085.</cite> [<a href="https://doi.org/10.1093/jnci/djy085" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29788099/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%C2%A0Natl%20Cancer%20Inst&amp;title=Biomarkers%20for%20homologous%20recombination%20deficiency%20in%20cancer&amp;author=M.M.%20Hoppe&amp;author=R.%20Sundar&amp;author=D.S.P.%20Tan&amp;author=A.D.%20Jeyasekharan&amp;volume=110&amp;issue=7&amp;publication_year=2018&amp;pages=704-713&amp;pmid=29788099&amp;doi=10.1093/jnci/djy085&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib16">
<span class="label">16.</span><cite>Pujade-Lauraine E., Brown J., Barnicle A., et al.  Homologous recombination repair gene mutations to predict olaparib plus bevacizumab efficacy in the first-line ovarian cancer PAOLA-1/ENGOT-ov25 trial. JCO Precis Oncol. 2023;7 doi: 10.1200/PO.22.00258.</cite> [<a href="https://doi.org/10.1200/PO.22.00258" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9928987/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36716415/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JCO%20Precis%20Oncol&amp;title=Homologous%20recombination%20repair%20gene%20mutations%20to%20predict%20olaparib%20plus%20bevacizumab%20efficacy%20in%20the%20first-line%20ovarian%20cancer%20PAOLA-1/ENGOT-ov25%20trial&amp;author=E.%20Pujade-Lauraine&amp;author=J.%20Brown&amp;author=A.%20Barnicle&amp;volume=7&amp;publication_year=2023&amp;pmid=36716415&amp;doi=10.1200/PO.22.00258&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib17">
<span class="label">17.</span><cite>Lynparza  European Medicines Agency. <a href="https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza#authorisation-details-section" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza#authorisation-details-section</a></cite>
</li>
<li id="bib18">
<span class="label">18.</span><cite>Roubaud G., Ozguroglu M., Penel N., et al.  Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: further analyses from the PROfound study. Eur J Cancer. 2022;170:73–84. doi: 10.1016/j.ejca.2022.04.016.</cite> [<a href="https://doi.org/10.1016/j.ejca.2022.04.016" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11919091/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35598359/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Cancer&amp;title=Olaparib%20tolerability%20and%20common%20adverse-event%20management%20in%20patients%20with%20metastatic%20castration-resistant%20prostate%20cancer:%20further%20analyses%20from%20the%20PROfound%20study&amp;author=G.%20Roubaud&amp;author=M.%20Ozguroglu&amp;author=N.%20Penel&amp;volume=170&amp;publication_year=2022&amp;pages=73-84&amp;pmid=35598359&amp;doi=10.1016/j.ejca.2022.04.016&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib19">
<span class="label">19.</span><cite>Cottrell K., Clark C.L., Penson R.T. An update on the safety of olaparib for treating ovarian cancer. Expert Opin Drug Saf. 2022;21(4):447–451. doi: 10.1080/14740338.2022.2047176.</cite> [<a href="https://doi.org/10.1080/14740338.2022.2047176" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35212587/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Expert%20Opin%20Drug%20Saf&amp;title=An%20update%20on%20the%20safety%20of%20olaparib%20for%20treating%20ovarian%20cancer&amp;author=K.%20Cottrell&amp;author=C.L.%20Clark&amp;author=R.T.%20Penson&amp;volume=21&amp;issue=4&amp;publication_year=2022&amp;pages=447-451&amp;pmid=35212587&amp;doi=10.1080/14740338.2022.2047176&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib20">
<span class="label">20.</span><cite>de Bono J., Mateo J., Fizazi K., et al.  Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382(22):2091–2102. doi: 10.1056/NEJMoa1911440.</cite> [<a href="https://doi.org/10.1056/NEJMoa1911440" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32343890/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%C2%A0Engl%20J%20Med&amp;title=Olaparib%20for%20metastatic%20castration-resistant%20prostate%20cancer&amp;author=J.%20de%20Bono&amp;author=J.%20Mateo&amp;author=K.%20Fizazi&amp;volume=382&amp;issue=22&amp;publication_year=2020&amp;pages=2091-2102&amp;pmid=32343890&amp;doi=10.1056/NEJMoa1911440&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib21">
<span class="label">21.</span><cite>Schram A.M., Colombo N., Arrowsmith E., et al.  Avelumab plus talazoparib in patients with BRCA1/2- or ATM-altered advanced solid tumors: results from JAVELIN BRCA/ATM, an open-label, multicenter, phase 2b, tumor-agnostic trial. JAMA Oncol. 2023;9:29–39. doi: 10.1001/jamaoncol.2022.5218.</cite> [<a href="https://doi.org/10.1001/jamaoncol.2022.5218" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9673021/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36394867/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Oncol&amp;title=Avelumab%20plus%20talazoparib%20in%20patients%20with%20BRCA1/2-%20or%20ATM-altered%20advanced%20solid%20tumors:%20results%20from%20JAVELIN%20BRCA/ATM,%20an%20open-label,%20multicenter,%20phase%202b,%20tumor-agnostic%20trial&amp;author=A.M.%20Schram&amp;author=N.%20Colombo&amp;author=E.%20Arrowsmith&amp;volume=9&amp;publication_year=2023&amp;pages=29-39&amp;pmid=36394867&amp;doi=10.1001/jamaoncol.2022.5218&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib22">
<span class="label">22.</span><cite>Wang W., Zhang X., Fang Y., et al.  Case report: olaparib shows satisfactory clinical outcomes against small cell esophageal carcinoma with ATM mutation. Front Oncol. 2022;12 doi: 10.3389/fonc.2022.808801.</cite> [<a href="https://doi.org/10.3389/fonc.2022.808801" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9036436/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35480123/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Oncol&amp;title=Case%20report:%20olaparib%20shows%20satisfactory%20clinical%20outcomes%20against%20small%20cell%20esophageal%20carcinoma%20with%20ATM%20mutation&amp;author=W.%20Wang&amp;author=X.%20Zhang&amp;author=Y.%20Fang&amp;volume=12&amp;publication_year=2022&amp;pmid=35480123&amp;doi=10.3389/fonc.2022.808801&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib23">
<span class="label">23.</span><cite>Bakr A., Oing C., Kocher S., et al.  Involvement of ATM in homologous recombination after end resection and RAD51 nucleofilament formation. Nucleic Acids Res. 2015;43(6):3154–3166. doi: 10.1093/nar/gkv160.</cite> [<a href="https://doi.org/10.1093/nar/gkv160" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4381069/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25753674/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nucleic%20Acids%20Res&amp;title=Involvement%20of%20ATM%20in%20homologous%20recombination%20after%20end%20resection%20and%20RAD51%20nucleofilament%20formation&amp;author=A.%20Bakr&amp;author=C.%20Oing&amp;author=S.%20Kocher&amp;volume=43&amp;issue=6&amp;publication_year=2015&amp;pages=3154-3166&amp;pmid=25753674&amp;doi=10.1093/nar/gkv160&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib24">
<span class="label">24.</span><cite>Curtin N.J. Targeting the DNA damage response for cancer therapy. Biochem Soc Trans. 2023;51(1):207–221. doi: 10.1042/BST20220681.</cite> [<a href="https://doi.org/10.1042/BST20220681" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9988002/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36606678/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biochem%20Soc%20Trans&amp;title=Targeting%20the%20DNA%20damage%20response%20for%20cancer%20therapy&amp;author=N.J.%20Curtin&amp;volume=51&amp;issue=1&amp;publication_year=2023&amp;pages=207-221&amp;pmid=36606678&amp;doi=10.1042/BST20220681&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib25">
<span class="label">25.</span><cite>Parvin S., Akter J., Takenobu H., et al.  ATM depletion induces proteasomal degradation of FANCD2 and sensitizes neuroblastoma cells to PARP inhibitors. BMC Cancer. 2023;23(1):313. doi: 10.1186/s12885-023-10772-y.</cite> [<a href="https://doi.org/10.1186/s12885-023-10772-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10077671/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37020276/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMC%20Cancer&amp;title=ATM%20depletion%20induces%20proteasomal%20degradation%20of%20FANCD2%20and%20sensitizes%20neuroblastoma%20cells%20to%20PARP%20inhibitors&amp;author=S.%20Parvin&amp;author=J.%20Akter&amp;author=H.%20Takenobu&amp;volume=23&amp;issue=1&amp;publication_year=2023&amp;pages=313&amp;pmid=37020276&amp;doi=10.1186/s12885-023-10772-y&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib26">
<span class="label">26.</span><cite>Tung N.M., Robson M.E., Ventz S., et al.  TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes. J Clin Oncol. 2020;38(36):4274–4282. doi: 10.1200/JCO.20.02151.</cite> [<a href="https://doi.org/10.1200/JCO.20.02151" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33119476/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%C2%A0Clin%20Oncol&amp;title=TBCRC%20048:%20phase%20II%20study%20of%C2%A0olaparib%20for%20metastatic%20breast%20cancer%20and%20mutations%20in%20homologous%20recombination-related%20genes&amp;author=N.M.%20Tung&amp;author=M.E.%20Robson&amp;author=S.%20Ventz&amp;volume=38&amp;issue=36&amp;publication_year=2020&amp;pages=4274-4282&amp;pmid=33119476&amp;doi=10.1200/JCO.20.02151&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib27">
<span class="label">27.</span><cite>Banerjee S., Moore K.N., Colombo N., et al.  Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22(12):1721–1731. doi: 10.1016/S1470-2045(21)00531-3.</cite> [<a href="https://doi.org/10.1016/S1470-2045(21)00531-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34715071/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol&amp;title=Maintenance%20olaparib%20for%20patients%20with%20newly%20diagnosed%20advanced%20ovarian%20cancer%20and%20a%20BRCA%20mutation%20(SOLO1/GOG%203004):%205-year%20follow-up%20of%20a%20randomised,%20double-blind,%20placebo-controlled,%20phase%203%20trial&amp;author=S.%20Banerjee&amp;author=K.N.%20Moore&amp;author=N.%20Colombo&amp;volume=22&amp;issue=12&amp;publication_year=2021&amp;pages=1721-1731&amp;pmid=34715071&amp;doi=10.1016/S1470-2045(21)00531-3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib28">
<span class="label">28.</span><cite>Hodgson D., Lai Z., Dearden S., et al.  Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD. Ann Oncol. 2021;32(12):1582–1589. doi: 10.1016/j.annonc.2021.08.2154.</cite> [<a href="https://doi.org/10.1016/j.annonc.2021.08.2154" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34500047/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Oncol&amp;title=Analysis%20of%20mutation%20status%20and%20homologous%20recombination%20deficiency%20in%20tumors%20of%20patients%20with%20germline%20BRCA1%20or%20BRCA2%20mutations%20and%20metastatic%20breast%20cancer:%20OlympiAD&amp;author=D.%20Hodgson&amp;author=Z.%20Lai&amp;author=S.%20Dearden&amp;volume=32&amp;issue=12&amp;publication_year=2021&amp;pages=1582-1589&amp;pmid=34500047&amp;doi=10.1016/j.annonc.2021.08.2154&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib29">
<span class="label">29.</span><cite>Gonzalez-Martin A., Desauw C., Heitz F., et al.  Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial. Eur J Cancer. 2022;174:221–231. doi: 10.1016/j.ejca.2022.07.022.</cite> [<a href="https://doi.org/10.1016/j.ejca.2022.07.022" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36067615/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Cancer&amp;title=Maintenance%20olaparib%20plus%20bevacizumab%20in%20patients%20with%20newly%20diagnosed%20advanced%20high-grade%20ovarian%20cancer:%20main%20analysis%20of%20second%20progression-free%20survival%20in%20the%20phase%20III%20PAOLA-1/ENGOT-ov25%20trial&amp;author=A.%20Gonzalez-Martin&amp;author=C.%20Desauw&amp;author=F.%20Heitz&amp;volume=174&amp;publication_year=2022&amp;pages=221-231&amp;pmid=36067615&amp;doi=10.1016/j.ejca.2022.07.022&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib30">
<span class="label">30.</span><cite>Devico Marciano N., Kroening G., Dayyani F., et al.  BRCA-mutated pancreatic cancer: from discovery to novel treatment paradigms. Cancers (Basel) 2022;14(10):2453. doi: 10.3390/cancers14102453.</cite> [<a href="https://doi.org/10.3390/cancers14102453" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9140002/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35626055/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers%20(Basel)&amp;title=BRCA-mutated%20pancreatic%20cancer:%20from%20discovery%20to%20novel%20treatment%20paradigms&amp;author=N.%20Devico%20Marciano&amp;author=G.%20Kroening&amp;author=F.%20Dayyani&amp;volume=14&amp;issue=10&amp;publication_year=2022&amp;pages=2453&amp;pmid=35626055&amp;doi=10.3390/cancers14102453&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib31">
<span class="label">31.</span><cite>Garajova I., Balsano R., Gelsomino F., Leonardi F. Olaparib as a single agent treatment in pre-treated metastatic pancreatic cancer patient harboring BRCA2 mutation: what could we expect? Tumori. 2022;108(6):NP30–NP33. doi: 10.1177/03008916221132589.</cite> [<a href="https://doi.org/10.1177/03008916221132589" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36299234/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Tumori&amp;title=Olaparib%20as%20a%20single%20agent%20treatment%20in%20pre-treated%20metastatic%20pancreatic%20cancer%20patient%20harboring%20BRCA2%20mutation:%20what%20could%20we%20expect?&amp;author=I.%20Garajova&amp;author=R.%20Balsano&amp;author=F.%20Gelsomino&amp;author=F.%20Leonardi&amp;volume=108&amp;issue=6&amp;publication_year=2022&amp;pages=NP30-NP33&amp;pmid=36299234&amp;doi=10.1177/03008916221132589&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib32">
<span class="label">32.</span><cite>Teke M.E., Saif A., Ryan C.E., Lux S.C., Hernandez J.M., Reiss K.A. A randomized study of olaparib or placebo in patients with surgically removed pancreatic cancer who have a BRCA1, BRCA2 or PALB2 mutation (the APOLLO trial) Ann Surg Oncol. 2022;29(9):5375–5376. doi: 10.1245/s10434-022-11917-2.</cite> [<a href="https://doi.org/10.1245/s10434-022-11917-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35668307/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Surg%20Oncol&amp;title=A%C2%A0randomized%20study%20of%20olaparib%20or%20placebo%20in%20patients%20with%20surgically%20removed%20pancreatic%20cancer%20who%20have%20a%20BRCA1,%20BRCA2%20or%20PALB2%20mutation%20(the%20APOLLO%20trial)&amp;author=M.E.%20Teke&amp;author=A.%20Saif&amp;author=C.E.%20Ryan&amp;author=S.C.%20Lux&amp;author=J.M.%20Hernandez&amp;volume=29&amp;issue=9&amp;publication_year=2022&amp;pages=5375-5376&amp;pmid=35668307&amp;doi=10.1245/s10434-022-11917-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib33">
<span class="label">33.</span><cite>Spizzo G., Puccini A., Xiu J., et al.  Molecular profile of BRCA-mutated biliary tract cancers. ESMO Open. 2020;5(3) doi: 10.1136/esmoopen-2020-000682.</cite> [<a href="https://doi.org/10.1136/esmoopen-2020-000682" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7312328/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32576609/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=ESMO%20Open&amp;title=Molecular%20profile%20of%20BRCA-mutated%20biliary%20tract%20cancers&amp;author=G.%20Spizzo&amp;author=A.%20Puccini&amp;author=J.%20Xiu&amp;volume=5&amp;issue=3&amp;publication_year=2020&amp;pmid=32576609&amp;doi=10.1136/esmoopen-2020-000682&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib34">
<span class="label">34.</span><cite>Katona B.W., Stadler Z.K., Robson M.E., Domchek S.M. RE: BRCA1 and BRCA2 gene mutations and colorectal cancer risk: systematic review and meta-analysis. J Natl Cancer Inst. 2019;111(5):522–523. doi: 10.1093/jnci/djz012.</cite> [<a href="https://doi.org/10.1093/jnci/djz012" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6510222/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30715414/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%C2%A0Natl%20Cancer%20Inst&amp;title=RE:%20BRCA1%20and%20BRCA2%20gene%20mutations%20and%20colorectal%20cancer%20risk:%20systematic%20review%20and%20meta-analysis&amp;author=B.W.%20Katona&amp;author=Z.K.%20Stadler&amp;author=M.E.%20Robson&amp;author=S.M.%20Domchek&amp;volume=111&amp;issue=5&amp;publication_year=2019&amp;pages=522-523&amp;pmid=30715414&amp;doi=10.1093/jnci/djz012&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib35">
<span class="label">35.</span><cite>Smeby J., Kryeziu K., Berg K.C.G., et al.  Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity. EBioMedicine. 2020;59 doi: 10.1016/j.ebiom.2020.102923.</cite> [<a href="https://doi.org/10.1016/j.ebiom.2020.102923" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7452640/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32799124/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=EBioMedicine&amp;title=Molecular%20correlates%20of%20sensitivity%20to%20PARP%20inhibition%20beyond%20homologous%20recombination%20deficiency%20in%20pre-clinical%20models%20of%20colorectal%20cancer%20point%20to%20wild-type%20TP53%20activity&amp;author=J.%20Smeby&amp;author=K.%20Kryeziu&amp;author=K.C.G.%20Berg&amp;volume=59&amp;publication_year=2020&amp;pmid=32799124&amp;doi=10.1016/j.ebiom.2020.102923&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib36">
<span class="label">36.</span><cite>Ghiringhelli F., Richard C., Chevrier S., Vegran F., Boidot R. Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein. World J Gastroenterol. 2016;22(48):10680–10686. doi: 10.3748/wjg.v22.i48.10680.</cite> [<a href="https://doi.org/10.3748/wjg.v22.i48.10680" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5192280/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28082821/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=World%20J%20Gastroenterol&amp;title=Efficiency%20of%20olaparib%20in%20colorectal%20cancer%20patients%20with%20an%20alteration%20of%20the%20homologous%20repair%20protein&amp;author=F.%20Ghiringhelli&amp;author=C.%20Richard&amp;author=S.%20Chevrier&amp;author=F.%20Vegran&amp;author=R.%20Boidot&amp;volume=22&amp;issue=48&amp;publication_year=2016&amp;pages=10680-10686&amp;pmid=28082821&amp;doi=10.3748/wjg.v22.i48.10680&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib37">
<span class="label">37.</span><cite>Martini G., Belli V., Napolitano S., et al.  Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer. ESMO Open. 2023;8(3) doi: 10.1016/j.esmoop.2023.101198.</cite> [<a href="https://doi.org/10.1016/j.esmoop.2023.101198" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10265597/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37119788/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=ESMO%20Open&amp;title=Establishment%20of%20patient-derived%20tumor%20organoids%20to%20functionally%20inform%20treatment%20decisions%20in%20metastatic%20colorectal%20cancer&amp;author=G.%20Martini&amp;author=V.%20Belli&amp;author=S.%20Napolitano&amp;volume=8&amp;issue=3&amp;publication_year=2023&amp;pmid=37119788&amp;doi=10.1016/j.esmoop.2023.101198&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib38">
<span class="label">38.</span><cite>Penson R.T., Valencia R.V., Cibula D., et al.  Olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1/2 mutation (SOLO3): a randomized phase III trial. J Clin Oncol. 2020;38(11):1164–1174. doi: 10.1200/JCO.19.02745.</cite> [<a href="https://doi.org/10.1200/JCO.19.02745" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7145583/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32073956/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%C2%A0Clin%20Oncol&amp;title=Olaparib%20versus%20nonplatinum%20chemotherapy%20in%20patients%20with%20platinum-sensitive%20relapsed%20ovarian%20cancer%20and%20a%20germline%20BRCA1/2%20mutation%20(SOLO3):%20a%20randomized%20phase%20III%20trial&amp;author=R.T.%20Penson&amp;author=R.V.%20Valencia&amp;author=D.%20Cibula&amp;volume=38&amp;issue=11&amp;publication_year=2020&amp;pages=1164-1174&amp;pmid=32073956&amp;doi=10.1200/JCO.19.02745&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib39">
<span class="label">39.</span><cite>Alberti A., Smussi D., Zamparini M., et al.  Treatment and outcome of metastatic parathyroid carcinoma: a systematic review and pooled analysis of published cases. Front Oncol. 2022;12 doi: 10.3389/fonc.2022.997009.</cite> [<a href="https://doi.org/10.3389/fonc.2022.997009" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9550213/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36226055/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Oncol&amp;title=Treatment%20and%20outcome%20of%20metastatic%20parathyroid%20carcinoma:%20a%20systematic%20review%20and%20pooled%20analysis%20of%20published%20cases&amp;author=A.%20Alberti&amp;author=D.%20Smussi&amp;author=M.%20Zamparini&amp;volume=12&amp;publication_year=2022&amp;pmid=36226055&amp;doi=10.3389/fonc.2022.997009&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="caption p"><span>Supplementary Table</span></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/10774963/bin/mmc1.xlsx" data-ga-action="click_feat_suppl" class="usa-link">mmc1.xlsx</a><sup> (11.3KB, xlsx) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material2_reqid_"><div class="caption p"><span>Supplementary Table</span></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/10774963/bin/mmc2.xlsx" data-ga-action="click_feat_suppl" class="usa-link">mmc2.xlsx</a><sup> (11.8KB, xlsx) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material3_reqid_"><div class="caption p"><span>Supplementary Table</span></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/10774963/bin/mmc3.xlsx" data-ga-action="click_feat_suppl" class="usa-link">mmc3.xlsx</a><sup> (11.9KB, xlsx) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material4_reqid_"><div class="caption p"><span>Supplementary Appendix 1</span></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/10774963/bin/mmc4.xlsx" data-ga-action="click_feat_suppl" class="usa-link">mmc4.xlsx</a><sup> (12.3KB, xlsx) </sup>
</div></div></section></section></section></section></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1016/j.esmoop.2023.102041"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/main.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (399.5 KB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/10774963/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/10774963/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC10774963%2F%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC10774963/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC10774963/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC10774963/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/37852034/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC10774963/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/37852034/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC10774963/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/10774963/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="1WUio8Ee7SqjbBmQF53sMDVMoX4lSLpKD6kva07MoAUDmHRRV4r2jLOsvPtyVwUf">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
